Naglazyme (Galsulfase) - Published Studies

Naglazyme Related Published Studies

Research related to Naglazyme (Galsulfase)

Thrombocytopenia associated with galsulfase treatment. [2011.07]

Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation. [2010.12]

Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures. [2010.09]

Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy. [2009.08]

A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase. [2009]

Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. [2008.12]

Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase). [2008.09]

Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase). [2008.06]

Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]). [2008.03]

Other possibly related research studies

Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. [2009]

Enzyme replacement therapy for the management of the mucopolysaccharidoses. [2009]

Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. [2010.04]

Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis? [2009.07]

Enzyme replacement therapy in the home setting for mucopolysaccharidosis VI: a survey of patient characteristics and physicians' early findings in the United States. [2009.01]

Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease. [2008.03]

[Overview of enzyme replacement therapy in mucopolysaccharidosis] [2007.03]

[Enzyme replacement therapy of lysosomal storage diseases]. [2010.12]